Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypocrisy of moral imperatives in the Israel-Hamas war.
Roth S, Wald HS, Spence NZ, Oratz R, Schwartz DM. Roth S, et al. Among authors: oratz r. Lancet. 2024 Apr 20;403(10436):1542. doi: 10.1016/S0140-6736(24)00241-1. Epub 2024 Apr 9. Lancet. 2024. PMID: 38608685 No abstract available.
When medical duty and advocacy are one-sided, both sides suffer.
Katz NT, Oratz R, Steinert Y, Wald R, Carmi R. Katz NT, et al. Among authors: oratz r. Lancet. 2024 Apr 20;403(10436):1540-1541. doi: 10.1016/S0140-6736(24)00239-3. Epub 2024 Apr 9. Lancet. 2024. PMID: 38608684 No abstract available.
Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.
Mashiach E, Alzate JD, De Nigris Vasconcellos F, Adams S, Santhumayor B, Meng Y, Schnurman Z, Donahue BR, Bernstein K, Orillac C, Bollam R, Kwa MJ, Meyers M, Oratz R, Novik Y, Silverman JS, Harter DH, Golfinos JG, Kondziolka D. Mashiach E, et al. Among authors: oratz r. J Neurooncol. 2024 May;168(1):99-109. doi: 10.1007/s11060-024-04651-0. Epub 2024 Apr 17. J Neurooncol. 2024. PMID: 38630386
Long-term Survival From Breast Cancer Brain Metastases in the Era of Modern Systemic Therapies.
Mashiach E, Alzate JD, De Nigris Vasconcellos F, Bernstein K, Donahue BR, Schnurman Z, Gurewitz J, Rotman LE, Adams S, Meyers M, Oratz R, Novik Y, Kwa MJ, Silverman JS, Sulman EP, Golfinos JG, Kondziolka D. Mashiach E, et al. Among authors: oratz r. Neurosurgery. 2024 Jan 1;94(1):154-164. doi: 10.1227/neu.0000000000002640. Epub 2023 Aug 15. Neurosurgery. 2024. PMID: 37581437 Review.
Early effectiveness and toxicity outcomes of reirradiation after breast conserving surgery for recurrent or new primary breast cancer.
Hardy-Abeloos C, Xiao J, Oh C, Barbee D, Perez CA, Oratz R, Schnabel F, Axelrod D, Guth A, Braunstein LZ, Khan A, Choi JI, Gerber N. Hardy-Abeloos C, et al. Among authors: oratz r. Breast Cancer Res Treat. 2023 Feb;198(1):43-51. doi: 10.1007/s10549-022-06853-4. Epub 2023 Jan 5. Breast Cancer Res Treat. 2023. PMID: 36604352
Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic.
Marks DK, Budhathoki N, Kucharczyk J, Fa'ak F, D'Abreo N, Kwa M, Plasilova M, Dhage S, Soe PP, Becker D, Hindenburg A, Lee J, Winner M, Okpara C, Daly A, Shah D, Ramdhanny A, Meyers M, Oratz R, Speyer J, Novik Y, Schnabel F, Jones SA, Adams S. Marks DK, et al. Among authors: oratz r. Oncologist. 2022 Mar 4;27(2):89-96. doi: 10.1093/oncolo/oyab042. Oncologist. 2022. PMID: 35641208 Free PMC article.
Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia.
Yin L, Klein EJ, Svigos K, Novice T, Gutierrez D, Oratz R, Lacouture ME, Powers M, Senna M, Shapiro J, Lo Sicco K. Yin L, et al. Among authors: oratz r. J Am Acad Dermatol. 2023 Jan;88(1):176-179. doi: 10.1016/j.jaad.2022.03.009. Epub 2022 Mar 9. J Am Acad Dermatol. 2023. PMID: 35278488 No abstract available.
Diabetes and differences in detection of incident invasive breast cancer.
Calip GS, Yu O, Boudreau DM, Shao H, Oratz R, Richardson SB, Gold HT. Calip GS, et al. Among authors: oratz r. Cancer Causes Control. 2019 May;30(5):435-441. doi: 10.1007/s10552-019-01166-2. Epub 2019 Apr 4. Cancer Causes Control. 2019. PMID: 30949885 Free PMC article.
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S. Kwa M, et al. Among authors: oratz r. Breast Cancer Res Treat. 2018 Feb;168(1):57-67. doi: 10.1007/s10549-017-4570-4. Epub 2017 Nov 9. Breast Cancer Res Treat. 2018. PMID: 29124456 Clinical Trial.
55 results